Pharmaceutical Executive January 23, 2024
Staff

The Osteoboost device has been shown to slow the loss of bone strength and density in postmenopausal women with osteopenia.

The FDA has cleared Bone Health Technologies’ wearable belt device for the treatment of low bone density in postmenopausal women. The regulatory action makes the Osteoboost belt the first non-pharmacological device-based prescription therapy to gain approval in the United States for the treatment of osteopenia.1

“[The] groundbreaking decision represents the first non-pharmacological therapy approved to treat this widespread and serious condition. With Osteoboost, we have a new treatment option—free of serious adverse events—that taps into the body’s natural mechanism to stimulate bone growth,” Bone Health Technologies CEO Laura Yecies said in a press release. “Women’s health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Wearable Health Tech: Innovations and Impacts on Chronic Disease Management
Driving Urgent Change To Optimize The Patient Experience
Sibionics Blood Glucose Sensor: Review
Dexcom invests $75M in Ōura, agrees to integrate smart rings and CGMs
Wearable Device Can Warn of Worsening Heart Failure

Share This Article